title: Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
abstract: OBJECTIVE
  An analysis of resource utilization and hospital costs associated with recurrent venous thromboembolism (VTE) is presented.
  
  
  METHODS
  A retrospective cohort analysis was conducted using a large U.S. hospital database. Patients with VTE-related hospitalization events during the period January-December 2010 were identified; data collection extended for up to 12 months after the index event. Postdischarge hospital resource use and total costs were compared in cohorts of patients with and without recurrent VTE. Regression analysis was performed to compare hospital costs and length of stay (LOS) during initial and subsequent VTE encounters.
  
  
  RESULTS
  Among the study population of 43,734 patients, 4% had postdischarge VTE-related events during the data collection period. The median and mean ± S.D. times to VTE recurrence were 48 days and 98 ± 106 days, respectively. Patients with recurrent VTE had more all-cause hospitalizations than those without recurrent VTE (mean ± S.D., 1.07 ± 0.96 versus 0.15 ± 0.53; p < 0.0001), more all-cause emergency room visits (mean ± S.D., 0.31 ± 0.66 versus 0.05 ± 0.31; p < 0.0001), and greater total costs (mean ± S.D., $28,353 ± $39,624 versus $17,712 ± $33,461; p < 0.0001). Relative to initial VTE admissions, admissions for recurrent VTE were, on average, associated with a 14% longer LOS (p = 0.0002) and a 22% higher total cost (p < 0.001).
  
  
  CONCLUSIONS
  Patients with recurrent VTE used more hospital resources than those without recurrent VTE. Readmissions for VTE were significantly longer and more costly than index encounters.
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ. juliancasciano@emaxhealth.net.
authors: Julian P
authors: JP
authors: Casciano
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ.
authors: Zenobia
authors: Z
authors: Dotiwala
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ.
authors: Robert
authors: R
authors: Kemp
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ.
authors: Chenghui
authors: C
authors: Li
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ.
authors: Jennifer
authors: J
authors: Cai
authors: Julian P. Casciano, B.S., is President and CEO; and Zenobia Dotiwala, M.S., is Manager, eMAX Health Systems, LLC, White Plains, NY. Robert Kemp, Ph.D., is Associate Professor, School of Pharmacy, University of Louisiana, Monroe. Chenghui Li, Ph.D., is Associate Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock. Jennifer Cai, M.S., M.P.H., is Associate Director, Health Economics & Outcomes Research; and Ronald Preblick, Pharm.D., M.P.H., is Director, Health Economics & Outcomes Research, Daiichi Sankyo, Inc., Parsippany, NJ.
authors: Ronald
authors: R
authors: Preblick
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D016208:Databases, Factual; D005260:Female; D006761:Hospitals; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000191:economics / Q000453:epidemiology; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000191:economics* / Q000453:epidemiology; D020246:Venous Thrombosis / Q000191:economics / Q000453:epidemiology